Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) on Wednesday reported a fourth quarter adjusted loss of $1.15, better than the Wall Street loss estimate of $1.32 • Ionis Pharmaceuticals stock is showing notable weakness. What’s pressuring IONS stock?Sales reached $203 million, beating the consensus of $156.09 million.Commercial revenue for the fourth quarter and the year ended Dec. 31, 2025, increased 64% and 49%, respectively, compared to the same periods in 2024.Tryngolza (olezarsen) product sales primarily drov ...